Salbutamol and around

Advances in Therapy, 2023

The role of as-needed inhaled short-acting b 2agonists (SABAs) in the management of asthma has become a subject of debate due to differing opinions in the professional community relating to the use of SABAs. In this article, we summarize the current position of SABAs when used as reliever medications and examine the challenges to appropriate use including a critique of the data that have led to the condemnation of SABA used as a reliever. We consider the evidence for the appropriate use of SABA as a reliever together with practical solutions to

Journal of Clinical Medicine

For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes. Instead, the more appropriate course is the use of a combined inhaled corticosteroid–fast acting beta agonist as a reliever. This paper discusses the issues associated with the use of SABA, the reasons that patients over-use SABA, difficulties that can be expected in overcoming SABA over-reliance in patients, and our evolving understanding of the use of “anti-inflammatory relievers” in our patients with asthma.

ACTA MEDICA IRANICA, 2020

Asthma is the most common chronic illness in children and is a major reason for pediatric emergency department visits. Beta-2 agonists are considered the most effective drugs for immediate relief in the symptoms. This study aimed to compare the effectiveness of salbutamol delivered via jet nebulizer with a metered-dose inhaler (MDI) plus a spacer for asthma exacerbation in the pediatric emergency departments. The study was a randomized control, parallel-group design in children with age ranging from 6 months to 14 years, presenting in the emergency department with an acute asthma attack. A total of 116 patients were recruited for the study. Sixty-two patients were enrolled in the MDI/spacer group, and 54 patients were in the nebulizer group. Patients were assessed at baseline (0 min) and 15, 30, 45 and 60 min after commencement of the nebulizer and MDI/spacer. The response of each group to treatment was compared. The parents were counseled for their child enrolment in the study, whi...

British Journal of Clinical Pharmacology, 2005

Aims The Aerodose® inhaler is a novel, palm-sized, breath actuated device which requires little patient coordination. This study compared the dose-response of salbutamol delivered by the Aerodose® Inhaler (Aerogen Inc., Mountain View, USA) vs Pari LC Plus jet nebulizer (Pari LC Plus; Pari GmbH, Starnberg, Germany) and Ventolin™ Evohaler™ HFA pMDI (Evohaler; Allen & Hanburys [GlaxoSmithkline], Uxbridge, UK). Methods Twenty-two moderate to severe asthmatic patients, mean (s.d.) age: 44.7 (9.4), F EV 1 : 58.1 (12.0), received 4 cumulative doubling doses of salbutamol in a randomised, investigator blind, balanced crossover design. Spirometry and systemic safety variables (heart rate, blood pressure, T wave amplitude, QTc interval and potassium) were measured at baseline and after each dose. Results Parallel regression analysis revealed that microgram relative potency ratios for the Aerodose® Inhaler to be five times more efficient for FEV 1 than either the Pari LC Plus (0.202, 90% CI: 0.189-0.216) or the Evohaler (0.202, 90% CI: 0.189-0.216), while there was no difference between Pari LC Plus vs Evohaler. Similarly, Aerodose® Inhaler vs. Pari LC Plus showed approximately five-fold greater potency for all systemic parameters, except blood pressure. As compared to the Evohaler, Aerodose® Inhaler had equivalent potency for plasma potassium and T wave amplitude, but demonstrated greater potency for heart rate and QT c interval. Conclusions This study has indicated therefore, that Aerodose® Inhaler is approximately five times as efficient as the Pari LC Plus and Evohaler in relative lung delivery of salbutamol in moderate to severe asthmatics.

Advances in Therapy

Introduction: Short-acting b 2-agonist (SABA) reliever overuse is common in asthma, despite availability of inhaled corticosteroid (ICS)-based maintenance therapies, and may be associated with increased risk of adverse events (AEs). This systematic literature review (SLR) and meta-analysis aimed to investigate the safety and tolerability of SABA reliever monotherapy for adults and adolescents with asthma, through analysis of randomized controlled trials (RCTs) and real-world evidence. Methods: An SLR of English-language publications between January 1996 and December 2021 included RCTs and observational studies of patients aged C 12 years treated with inhaled SABA reliever monotherapy (fixed dose or as needed) for C 4 weeks. Studies of terbutaline and fenoterol were excluded. Meta-analysis feasibility was dependent on cross-trial data

Revue Française d'Allergologie et d'Immunologie Clinique, 1988

Journal of Asthma and Allergy, 2021

Purpose: Many patients with asthma still have insufficient disease control, despite the availability of effective treatment options. A substantial proportion of patients appear to rely more on short-acting beta 2-agonist (SABA) rather than on anti-inflammatory maintenance treatment. The aim of this study was to describe differences in indicators of asthma symptoms and exacerbations among patients using more or less SABA than the guidelinerecommended threshold of <3 times/week. Patients and Methods: Data from Dutch respondents in the European REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey were used in this post hoc analysis. The survey included asthma patients aged 18-50 years with at least two prescriptions for their asthma in the past two years. SABA use was categorized into two groups: <3 (low-SABA users) or ≥3 (high-SABA users) times in the last week. Results: Of the 736 asthma patients, 21% did not use SABA and 19% used SABA 1 to 2 times (all low SABA users) and 60% used SABA ≥3 times (high SABA users) in the last week. The majority of high and low SABA users also reported using an ICS-containing treatment. Significant differences were found for all indicators related to exacerbations (p<0.001): high SABA users more frequently used antibiotics and oral steroids, more frequently visited the emergency departments or needed an overnight hospital stay. Indicators of asthma symptoms were not significantly different between both groups. Conclusion: The majority of a Dutch asthmatic population reported high SABA use and had frequent moderate/severe exacerbations. More effective interventions are needed to change healthcare providers' and patients' behaviours to improve care and reduce SABA (over)use.

Pediatric Research, 1985

INTRODUCCIÓN "En verdad El habla de todas estas cosas en todas sus cartas. Ellas contienen algunos conceptos que son difíciles de entender, conceptos que los no instruidos e inestables distorsionan, para su propia destrucción, como hacen con las otras Escrituras. Pero ustedes, queridos amigos, sabiendo esto de antemano, cuídense para que no sean llevados por los errores de los malvados y caigan de su posición firme. Y permanezcan creciendo en gracia y conocimiento de nuestro Adón Salvador, Yeshúa Ha Mashíaj. ¡A Él sea la gloria, ahora y eternamente! Amen".

Cadmo Suplemento 4 Homenagem JAR Tomo I , 2023

The article presents a new Roman Lusitanian amphora Dressel 14 type stamp QSR found in Belém (near Lisbon) without any primary context. Based on a wide historical approach we discuss the possible functional uses of the Belém area (ancient Restelo beach) in Roman times. The corpus of known QSR Lusitanian amphora stamp and its geographical distribution can be seen as interesting proxy on domestic Lusitanian trade.